Loading patent…
AssigneeLudwig Institute for Cancer Research
InventorsMarta Lomnytska, Anna Dubrovska, Ulf Hellman, Nataliya Volodko, Serhiy Souchelnytskyi
Estimating the term…
Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer, using two-dimensional gel electrophoresis and MALDI TOF mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients, as compared to samples from noncancer cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients, and 31 individuals who were either healthy or had noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. The results indicate that cSHMT, Tbx3, utrophin and truncated forms thereof can be used as components of multiparameter monitoring of ovarian and breast cancer.
A diagnostic method for ovarian and/or breast cancer in a patient comprising the steps of:
A protein marker selected from the group consisting of cSHMT, Tbx3, utrophin and a truncated form of any one of these proteins.
An antibody raised against a protein selected from the group consisting of of cSHMT, Tbx3, utrophin and a truncated form of any one of these proteins.
A prognostic method for ovarian and/or breast cancer in a patient known already to have ovarian and/or breast cancer comprising the steps of:
A microarray of proteins and other markers for use in the diagnosis and/or prognosis of ovarian and/or breast cancer which comprises one or more markers selected from cSHMT, Tbx3, utrophin and truncated forms thereof in combination with one or more previously known markers.
Dependencies are inferred from the claim text.